Second test-run DUR program hits obstacle

Published: 2009-11-20 06:57:00

Updated: 2009-11-20 06:57:00

The ongoing Drug Utilization Review (DUR) program in Cheju has hit a snag as doctors have not joined it due to poor computerized system, pharmaceutical business sources said recently.

According to the sources, pharmacists only have participated in the program in the absence of medical institut...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK